How I Treat T-Cell Lymphomas
Steven M. Horwitz, MD, Memorial Sloan Kettering Cancer Center
Friday, September 19, 2017 2:30 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Establishing an accepted standard therapy in T-cell lymphomas remains elusive. This is, in part, due to the heterogeneity of the diseases as well as the too often suboptimal responses to commonly used upfront treatment strategies such as CHOP. Dr. Horwitz will review the current commonly used approaches highlighting where they are successful and where they appear inadequate. Increasingly, active agents and strategies in the relapsed setting (e.g., epigenetic modifiers, antibody drug conjugates, molecular targets, and checkpoint inhibitors) are providing additional treatment options at relapse as well as informing strategies for subtype-specific approaches in the upfront setting. Dr. Horwitz will review data for these newer approaches and how they are impacting current clinical trials.
About the Speaker
Steven M. Horwitz, MD, is an Associate Attending in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City, where he divides his time between the clinical care of lymphoma patients and clinical research focused primarily on developing new treatments for T-cell, NK, and cutaneous lymphomas. He is on the Board of Directors of the Cutaneous Lymphoma Foundation and the United States Cutaneous Lymphoma Consortium. He is also a member of the executive committee of the International T-cell Registry and is a member of the NCCN’s Non-Hodgkin’s Lymphoma Panel. Dr. Horwitz’s efforts have contributed to the approval of several new therapies for T-cell lymphomas as well as new guidelines for PTCL, NK/T-cell, and cutaneous lymphomas.
back to top